Status:

COMPLETED

Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD)

Lead Sponsor:

University of Cincinnati

Collaborating Sponsors:

National Institute on Drug Abuse (NIDA)

University of Colorado, Denver

Conditions:

ADHD

Substance Abuse

Eligibility:

All Genders

13-18 years

Phase:

PHASE3

Brief Summary

The purpose of this study is to determine the efficacy of osmotic-release methylphenidate (OROS-MPH) versus placebo for the treatment of ADHD in adolescents with SUD.

Detailed Description

Research shows a high prevalence of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents with substance abuse disorders and indicates that they have poorer substance use treatment outcomes a...

Eligibility Criteria

Inclusion

  • Meet Diagnostic and Statistical Manual for Mental Disorders, 4th Edition (DSM-IV) diagnostic criteria for ADHD
  • Meet DSM-IV diagnostic criteria for at least one non-nicotine substance use disorder
  • Has a DSM-IV ADHD Symptom Checklist score ≥ 22 derived from the adolescent-completed checklist

Exclusion

  • Serious medical illness
  • History of tic disorder
  • Pregnant or breastfeeding
  • Meet DSM-IV criteria for current or life-time psychotic disorder
  • Meet DSM-IV criteria for current or life-time bipolar disorder
  • Requires/or prescribed other concurrent psychotropic medication
  • Taking any medications that may produce interactions with OROS-MPH
  • Opiate dependence
  • Methamphetamine abuse or dependence
  • Suicidal risk
  • Enrolled in an inpatient, residential, day treatment, or outpatient substance abuse program within 28 days prior to signing consent

Key Trial Info

Start Date :

February 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2008

Estimated Enrollment :

303 Patients enrolled

Trial Details

Trial ID

NCT00264797

Start Date

February 1 2006

End Date

October 1 2008

Last Update

June 7 2013

Active Locations (12)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (12 locations)

1

Synergy Treatment Center

Denver, Colorado, United States, 80219

2

Gateway Community Services

Jacksonville, Florida, United States, 32211

3

Operation PAR, Inc.

St. Petersburg, Florida, United States, 33709

4

Mountain Manor Treatment Programs

Baltimore, Maryland, United States, 21229